FDA Approves Lilly’s Foundayo Oral GLP-1 Pill
The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.
-
By
-
Kathryn Wighton
-
April 1, 2026
-
Objective:
To provide a new treatment option for chronic weight management in adults with obesity or overweight and weight-related medical conditions.
Key Findings:
- Orforglipron demonstrated significant weight loss in adults with obesity or overweight.
- Mean weight loss across all participants was 25 pounds (11.1%) vs 5.3 pounds (2.1%) with placebo.
- Common adverse events included nausea, diarrhea, constipation, and vomiting.
Interpretation:
Orforglipron offers a new oral treatment option for weight management, showing significant efficacy and safety considerations.
Limitations:
- Warnings for potential thyroid tumors, including thyroid cancer.
- Not recommended for patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Conclusion:
Orforglipron is a promising new oral GLP-1 receptor agonist for weight management, with significant weight loss outcomes and cardiometabolic benefits.
